Merck KGaA in push to become twice as productive in drug development

FRANKFURT (Reuters) – Germany’s Merck KGaA on Monday said it aims to double the productivity of its research and development into oncology, neurology and immunology treatments.

As part of the productivity push, the drugmaker aims to introduce one new product or major new use for an existing product every 1.5 years on average.

The company is holding an investor day on its healthcare research and development strategy on Monday.

(Reporting by Ludwig Burger; Editing by Paul Carrel)